BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26194312)

  • 1. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
    Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.
    Toledo JB; Xie SX; Trojanowski JQ; Shaw LM
    Acta Neuropathol; 2013 Nov; 126(5):659-70. PubMed ID: 23812320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
    Shoji M
    Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
    Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
    BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
    J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.